Zudena is one of the four molecules investigated for the treatment of erectile dysfunction with proven clinical efficacy, high safety and acceptability to the patient. The unique qualities of Zudena distinguish it from commercially available inhibitors of other members of the group focfodiesterazy fifth type.
Zudena enjoy rapid and predictable onset of action, duration of up to 24 hours, high in the class of PDE-5 inhibitors, the safety profile, Zudena not have testicular toxicity. Certainly, all of these properties will be the best in its segment.
Zudena is a drug for treatment of erectile dysfunction. Is a reversible selective inhibitor of cGMP-specific phosphodiesterase type 5 (PDE5).
Zudena no direct relaxing effect on isolated corpus cavernosum, but enhances sexual stimulation relaxing effect of nitric oxide by inhibiting PDE-5, responsible for the breakdown of cGMP in the cavernous body. The result is relaxation of smooth muscles of arteries and blood flow to the tissues of the penis that causes erections. The drug has no effect in the absence of sexual stimulation.
Zudena improves erection and the possibility of successful sexual intercourse. The action of the drug has an optimal duration - up to 24 h. The effect is manifested as early as 30 minutes after taking the drug in the presence of sexual arousal.
Treatment of erection disorders, characterized by the inability to achieve or maintain penile erection sufficient for satisfactory sexual intercourse.
Pills taken by mouth, with or without food, for 30 minutes before the alleged sexual activity. Recommended dose - 100 mg. If necessary, taking into account individual performance and portability, the dose may be increased to 200 mg. The maximum recommended frequency of application - 1 times / day.
Sexual activity is a potential risk for patients with cardiovascular disease, hypertension, so treatment of sexual dysfunctions, including use of Zudena, should not hold for men with heart disease, in which sexual activity is not recommended.
Patients with obstruction of blood outflow from the left ventricle (aortic stenosis) may be more sensitive to the action of vasodilators, including inhibitors of PDE. Despite the lack of clinical trials of cases of prolonged erection (longer than 4 hours) and priapism (painful erection lasting more than 6 h), such phenomena are peculiar to this class of drugs. In the event of an erection lasting more than 4 hours (regardless of pain), patients should immediately seek medical help. In the absence of timely treatment of priapism can lead to irreversible damage to the erectile tissue and erectile function.
